Zoetis Advances Avian Health with H5N2 Vaccine Amid HPAI Outbreak

Zoetis Steps Up in Avian Health Amid HPAI Crisis

Zoetis Inc. has made significant strides in animal health, recently securing a conditional license from the U.S. Department of Agriculture's Center for Veterinary Biologics for its H5N2 subtype Avian Influenza Vaccine, aimed specifically at protecting chickens. This development comes as the poultry industry faces an urgent need for effective solutions to counter the Highly Pathogenic Avian Influenza (HPAI) outbreak that has impacted over 150 million birds in the U.S. since February 2022. The license signals Zoetis's commitment to addressing avian health challenges and reflects the company's long-standing expertise in developing vaccines against avian influenza.

The conditional license was granted after Zoetis successfully demonstrated the safety, purity, and expected efficacy of the H5N2 vaccine based on serological data. This achievement is a part of Zoetis's broader strategy to enhance its portfolio of innovative products. Mahesh Kumar, Ph.D., senior vice president at Zoetis, emphasizes the company’s proactive approach in responding to new strains of HPAI, which aligns with its history of vaccine development dating back to 2001-02. The firm previously secured a conditional license for the H5N1 vaccine in 2016, which was utilized to protect endangered species like the California condor, showcasing Zoetis's commitment to both commercial and conservation efforts.

Looking ahead, Zoetis aims to build on its recent accomplishments in the poultry sector while continuing to bolster its operational growth. The company recorded a robust financial performance for the fourth quarter and the full year of 2024, reporting revenues of $2.3 billion and $9.3 billion, respectively. This success is driven by increasing demand for innovative animal health products, particularly in its companion animal and livestock segments. As Zoetis endeavors to maintain this momentum, its advancements in vaccine development, like the H5N2, will play a crucial role in strengthening its position in the global animal health market.

In addition to its recent vaccine developments, Zoetis has also divested its medicated feed additive product portfolio, which has positively impacted its organic operational growth rates. The company reported a notable increase in revenue growth across both domestic and international markets, indicating a successful adaptation to market demands. With a dedicated workforce of approximately 13,800 employees, Zoetis continues to reinforce its mission of nurturing both the world and humankind through comprehensive animal care solutions.